These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 26474837)
1. A novel protective formulation of Palmitoylethanolamide in experimental model of contrast agent induced nephropathy. Cordaro M; Impellizzeri D; Bruschetta G; Siracusa R; Crupi R; Di Paola R; Esposito E; Cuzzocrea S Toxicol Lett; 2016 Jan; 240(1):10-21. PubMed ID: 26474837 [TBL] [Abstract][Full Text] [Related]
2. Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. Ahmad A; Mondello S; Di Paola R; Mazzon E; Esposito E; Catania MA; Italiano D; Mondello P; Aloisi C; Cuzzocrea S Eur J Pharmacol; 2012 Jan; 674(2-3):397-406. PubMed ID: 22094062 [TBL] [Abstract][Full Text] [Related]
3. N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress. Mattace Raso G; Simeoli R; Russo R; Santoro A; Pirozzi C; d'Emmanuele di Villa Bianca R; Mitidieri E; Paciello O; Pagano TB; Orefice NS; Meli R; Calignano A Pharmacol Res; 2013 Oct; 76():67-76. PubMed ID: 23917217 [TBL] [Abstract][Full Text] [Related]
4. Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis. Di Paola R; Impellizzeri D; Fusco R; Cordaro M; Siracusa R; Crupi R; Esposito E; Cuzzocrea S Pharmacol Res; 2016 Sep; 111():405-412. PubMed ID: 27402190 [TBL] [Abstract][Full Text] [Related]
5. The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice. Impellizzeri D; Peritore AF; Cordaro M; Gugliandolo E; Siracusa R; Crupi R; D'Amico R; Fusco R; Evangelista M; Cuzzocrea S; Di Paola R FASEB J; 2019 Oct; 33(10):11364-11380. PubMed ID: 31344333 [TBL] [Abstract][Full Text] [Related]
6. Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice. Di Paola R; Impellizzeri D; Mondello P; Velardi E; Aloisi C; Cappellani A; Esposito E; Cuzzocrea S Shock; 2012 Oct; 38(4):356-66. PubMed ID: 22772472 [TBL] [Abstract][Full Text] [Related]
7. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. Impellizzeri D; Bruschetta G; Cordaro M; Crupi R; Siracusa R; Esposito E; Cuzzocrea S J Neuroinflammation; 2014 Aug; 11():136. PubMed ID: 25164769 [TBL] [Abstract][Full Text] [Related]
9. Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. D'Amico R; Monaco F; Siracusa R; Cordaro M; Fusco R; Peritore AF; Gugliandolo E; Crupi R; Cuzzocrea S; Di Paola R; Impellizzeri D; Genovese T Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768820 [TBL] [Abstract][Full Text] [Related]
10. Protective Effects of Ultramicronized Palmitoylethanolamide (PEA-um) in Myocardial Ischaemia and Reperfusion Injury in VIVO. Di Paola R; Cordaro M; Crupi R; Siracusa R; Campolo M; Bruschetta G; Fusco R; Pugliatti P; Esposito E; Cuzzocrea S Shock; 2016 Aug; 46(2):202-13. PubMed ID: 26844976 [TBL] [Abstract][Full Text] [Related]
11. Administration of iodinated contrast in patients with pre-existing renal failure: a review. Spinazzi A; Pozzi Mucelli R Radiol Med; 2004; 107(1-2):88-97. PubMed ID: 15031700 [TBL] [Abstract][Full Text] [Related]
12. Effect of dietary supplementation with ultramicronized palmitoylethanolamide in maintaining remission in cats with nonflea hypersensitivity dermatitis: a double-blind, multicentre, randomized, placebo-controlled study. Noli C; Della Valle MF; Miolo A; Medori C; Schievano C; Vet Dermatol; 2019 Oct; 30(5):387-e117. PubMed ID: 31237065 [TBL] [Abstract][Full Text] [Related]
13. Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain. Ardizzone A; Fusco R; Casili G; Lanza M; Impellizzeri D; Esposito E; Cuzzocrea S Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671213 [TBL] [Abstract][Full Text] [Related]
15. A novel rat model of contrast-induced nephropathy based on dehydration. Liu K; Zhou LY; Li DY; Cheng WJ; Yin WJ; Hu C; Xie YL; Wang JL; Zuo SR; Chen LH; Zhou G; Zuo XC J Pharmacol Sci; 2019 Sep; 141(1):49-55. PubMed ID: 31611174 [TBL] [Abstract][Full Text] [Related]
16. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results. Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269 [TBL] [Abstract][Full Text] [Related]
17. A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. Britti D; Crupi R; Impellizzeri D; Gugliandolo E; Fusco R; Schievano C; Morittu VM; Evangelista M; Di Paola R; Cuzzocrea S BMC Vet Res; 2017 Aug; 13(1):229. PubMed ID: 28768536 [TBL] [Abstract][Full Text] [Related]
18. Epidemiology of contrast material-induced nephropathy in the era of hydration. Balemans CE; Reichert LJ; van Schelven BI; van den Brand JA; Wetzels JF Radiology; 2012 Jun; 263(3):706-13. PubMed ID: 22535561 [TBL] [Abstract][Full Text] [Related]
19. Neutrophil gelatinase-associated lipocalin as an early marker of contrast-induced nephropathy after coronary angiography. Alharazy SM; Kong N; Saidin R; Gafor AH; Maskon O; Mohd M; Zakaria SZ Angiology; 2014 Mar; 65(3):216-23. PubMed ID: 23378196 [TBL] [Abstract][Full Text] [Related]
20. Neutrophil gelatinase-associated lipocalin (NGAL): a promising biomarker of contrast-induced nephropathy after computed tomography. Filiopoulos V; Biblaki D; Vlassopoulos D Ren Fail; 2014 Jul; 36(6):979-86. PubMed ID: 24673459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]